Cargando…

Mutant KRAS Exosomes Influence the Metabolic State of the Colon Microenvironment

Detalles Bibliográficos
Autores principales:	Preet, Ranjan, Dixon, Dan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924741/ https://www.ncbi.nlm.nih.gov/pubmed/29713668 http://dx.doi.org/10.1016/j.jcmgh.2018.01.021

Ejemplares similares

Mutant KRAS Exosomes Alter the Metabolic State of Recipient Colonic Epithelial Cells
por: Zhang, Qin, et al.
Publicado: (2018)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes
por: Dou, Yongchao, et al.
Publicado: (2016)

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer
por: Aguilera, Oscar, et al.
Publicado: (2016)

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
por: Dias Carvalho, Patrícia, et al.
Publicado: (2019)

Carcinoma-derived exosomes modify microenvironment
por: Maitland, Norman J.
Publicado: (2015)

CRC-derived exosomes containing the RNA binding protein HuR promote lung cell proliferation by stabilizing c-Myc mRNA
por: Xiao, Hui, et al.
Publicado: (2022)

Targeting the PI3K signaling pathway in KRAS mutant colon cancer
por: Hong, Suntaek, et al.
Publicado: (2015)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Does KRAS Play a Role in the Regulation of Colon Cancer Cells-Derived Exosomes?
por: Eng, Shu-Kee, et al.
Publicado: (2021)

The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer
por: Tanjak, Pariyada, et al.
Publicado: (2023)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

The Specific Gravity-Free Method for the Isolation of Circulating Tumor KRAS Mutant DNA and Exosome in Colorectal Cancer
por: Lee, Tae Hee, et al.
Publicado: (2021)

KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
por: Wang, Guihua, et al.
Publicado: (2019)

Divide and conquer: towards isoform-specific diagnosis and therapy of KRAS-mutant lung cancer
por: Allemann, Anna T., et al.
Publicado: (2023)

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
por: Kerr, Emma, et al.
Publicado: (2016)

Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ
por: Liu, Yi, et al.
Publicado: (2022)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Tumor Microenvironment and Metabolism
por: Yang, Li V.
Publicado: (2017)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Cyclin D1 expression in KRAS mutant non-small cell lung cancer—old wine into new skins
por: Goh, Kah Yee, et al.
Publicado: (2020)

Role of tissue microenvironment resident adipocytes in colon cancer
por: Tabuso, Maria, et al.
Publicado: (2017)

Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer
por: Yan, Yan, et al.
Publicado: (2020)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Development of an exosome-related and immune microenvironment prognostic signature in colon adenocarcinoma
por: Cui, Guoliang, et al.
Publicado: (2022)

Quo vadis, Kras?
por: Schneider, Günter, et al.
Publicado: (2013)

KRAS-dependent sorting of miRNA to exosomes
por: Cha, Diana J, et al.
Publicado: (2015)

Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
por: Suzuki, Tatsunori, et al.
Publicado: (2021)

Editorial On “Exosomes, Their Biogenesis and Role in Inter-Cellular Communication, Tumor Microenvironment and Cancer Immunotherapy”
por: Golubovskaya, Vita, et al.
Publicado: (2020)

The Influence of the Cancer Microenvironment on the Process of Metastasis
por: Frost, Andra R., et al.
Publicado: (2012)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Exosomal cargos-mediated metabolic reprogramming in tumor microenvironment
por: Tan, Shiming, et al.
Publicado: (2023)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
por: Best, Sarah A., et al.
Publicado: (2019)

(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
por: Richardson, Leland G., et al.
Publicado: (2019)

Understanding KRAS for better targeting
por: Patel, Ronak, et al.
Publicado: (2023)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

Detection of circulating KRAS mutant DNA in extracellular vesicles using droplet digital PCR in patients with colon cancer
por: Choi, Jeesoo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5vj5t4hilfn0vf1m8l3dlhtip0